Jpmorgan Chase & CO Ardelyx, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Ardelyx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 387,144 shares of ARDX stock, worth $1.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

387,144

Previous 381,051 1.6%

Holding current value

$1.99 Million

Previous $2.82 Million 5.53%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$5.28 - $7.57 $32,171 - $46,124	6,093 Added 1.6%	387,144 $2.67 Million
Q2 2024 Aug 12, 2024	BUY	$5.89 - $9.31 $806,871 - $1.28 Million	136,990 Added 56.13%	381,051 $2.82 Million
Q1 2024 May 10, 2024	SELL	$6.05 - $9.74 $666,685 - $1.07 Million	-110,196 Reduced 31.11%	244,061 $1.78 Million
Q4 2023 Feb 12, 2024	SELL	$3.29 - $6.64 $3.28 Million - $6.62 Million	-997,285 Reduced 73.79%	354,257 $2.2 Million
Q3 2023 Nov 14, 2023	SELL	$3.3 - $4.83 $48,902 - $71,575	-14,819 Reduced 1.08%	1,351,542 $5.51 Million
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $738,313 - $1.13 Million	228,580 Added 20.09%	1,366,361 $4.63 Million
Q1 2023 May 11, 2023	SELL	$2.68 - $4.79 $556,217 - $994,135	-207,544 Reduced 15.43%	1,137,781 $5.45 Million
Q4 2022 Feb 13, 2023	BUY	$1.22 - $2.85 $1.64 Million - $3.83 Million	1,345,217 Added 1245571.25%	1,345,325 $3.83 Million
Q2 2022 Aug 11, 2022	SELL	$0.51 - $1.17 $23,112 - $53,022	-45,318 Reduced 99.76%	108 $0
Q1 2022 May 11, 2022	BUY	$0.65 - $1.18 $8,305 - $15,076	12,777 Added 39.13%	45,426 $48,000
Q4 2021 Feb 10, 2022	SELL	$0.86 - $1.7 $6,143 - $12,144	-7,144 Reduced 17.95%	32,649 $36,000
Q3 2021 Nov 12, 2021	BUY	$1.27 - $8.17 $50,537 - $325,108	39,793 New	39,793 $52,000

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $796M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Ardelyx, Inc. Transaction History